Optimal Stereotactic Body Radiotherapy Dosage For Hepatocellular Carcinoma

• DOI: 10.1101/2020.02.27.20028621
• Publication Date: 2020-02-27T22:55:13Z
• Authors: Ting-Shi Su; Ying Zhou; Yong Huang; Tao Cheng; Ping Liang; Shi-Xiong Liang; Le-Qun Li
• Keywords: Interquartile range

Abstract Background and purpose The optimal dose fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes degrees cirrhosis. We compared the effectiveness dosing regimens (HCC). Methods materials This single-center retrospective study included 604 patients treated during 2011-2017. Biologically effective (BED 10 ) equivalent in 2 Gym fractions (EQD were assumed at an α/β ratio 10. Overall survival (OS), local recurrence-free rate (LRF), intrahepatic (IRF), progression-free (PFS) was evaluated univariable propensity-score matched analyses. Results Median tumor size 5.2 cm (interquartile range [IQR], 1.1-21.0). follow-up 31 months surviving (IQR, 3-82). High radiotherapy correlated with better OS, PFS, LRF IRF. Different post-SBRT IRF rates observed ablative (SART) BED ≥100 Gy, SBRT EQD ≥74 Gy <100 conservative (SCRT) <74 Gy. Conclusions outcomes. If by normal tissue, we recommend SART as a first-line or second-line radical dose. Otherwise, SCRT is recommended palliative irradiation.